We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ProPhase Labs Inc | NASDAQ:PRPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.90% | 2.25 | 2.02 | 2.31 | 2.44 | 2.195 | 2.27 | 12,047 | 00:59:53 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of the Exchange Act:
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 4.01. Changes in Registrant’s Certifying Accountant.
On September 30, 2024, Morison Cogen LLP (“Morison”), the independent registered public accounting firm of ProPhase Labs, Inc., a Delaware corporation (the “Company”), decided to exit the PCAOB audit business. Based on this decision, the firm circulated a letter to the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company notifying them of such. The firm has therefore resigned as the independent registered public accounting firm of the Company, effective as of September 30, 2024.
The Company is in the final stages of engaging a new independent registered public accounting firm to replace Morison and expects to announce the engagement in the near future.
During the fiscal years ended December 31, 2023 and 2022, and the subsequent interim periods through June 30, 2024, there were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K), except for (i) the adverse opinion on internal control over financial reporting in Morison’s Report in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) and (ii) the material weaknesses due to the Company’s lack of effective internal controls over financial reporting as disclosed in “Part II, Item 9A. Controls and Procedures” of the Form 10-K and “Part I, Item 4. Controls and Procedures” of the Company’s subsequent quarterly reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024.
During the Company’s fiscal years ended December 31, 2023 and 2022, and through the date of Morison’s resignation, there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and Morison on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures which disagreements, if not resolved to the satisfaction of Morison would have caused Morison to make reference thereto in their report on the financial statements for such year.
The Company provided Morison with a copy of the disclosures it is making in this Current Report on Form 8-K in accordance with Item 304(a) of Regulation S-K and requested that Morison furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements contained herein. A copy of Morison’s letter, dated October 4, 2024 is filed as Exhibit 16.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are being filed herewith:
No. | Description | |
16.1 | Letter from Morison Cogen, dated October 4, 2024 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ProPhase Labs, Inc. | ||
By: | /s/ Ted Karkus | |
Ted Karkus | ||
Chairman of the Board and Chief Executive Officer | ||
Date: October 4, 2024 |
Exhibit 16.1
October 4, 2024
Securities and Exchange Commission
100 F Street NE
Washington, DC 20549
Ladies and Gentlemen:
We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on September 30, 2024, to be filed by our former client, ProPhase Labs, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm.
Very truly yours,
Morison Cogen LLP
Blue Bell, Pennsylvania
Cover |
Sep. 30, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 30, 2024 |
Entity File Number | 000-21617 |
Entity Registrant Name | PROPHASE LABS, INC |
Entity Central Index Key | 0000868278 |
Entity Tax Identification Number | 23-2577138 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 711 Stewart Avenue |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Garden City |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 11530 |
City Area Code | (215) |
Local Phone Number | 345-0919 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0005 |
Trading Symbol | PRPH |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year ProPhase Labs Chart |
1 Month ProPhase Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions